Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone (WSE-SCZ)
The Effectiveness of Ashwagandha Extract as an Adjuvant Therapy in Reducing Interleukin-1β Levels and Positive and Negative Syndrome Scale (PANSS) Scores in Schizophrenia Patients Receiving Risperidone
This study aims to evaluate the effectiveness of Ashwagandha (Withania somnifera) extract as an adjuvant therapy in patients with schizophrenia who are receiving risperidone. Schizophrenia is a chronic mental disorder associated with neuroinflammation and immune dysregulation, including increased levels of pro-inflammatory cytokines such as interleukin-1 beta (IL-1β).
In this study, patients diagnosed with schizophrenia are given standard treatment with risperidone, with or without additional Ashwagandha extract. The primary outcomes are changes in Interleukin-1β levels and clinical symptoms assessed using the Positive and Negative Syndrome Scale (PANSS).
The study aims to determine whether Ashwagandha extract supplementation can reduce inflammation and improve clinical symptoms in patients with schizophrenia. The findings support the use of Ashwagandha extract as a complementary therapy to enhance treatment outcomes in schizophrenia.
調査の概要
詳細な説明
This randomized controlled trial was conducted at South Sulawesi Mental Hospital (RSKD Dadi), South Sulawesi Province, Makassar, Indonesia.
Schizophrenia is a chronic and severe psychiatric disorder characterized by disturbances in perception, cognition, emotion, and behavior. In addition to neurotransmitter imbalances, increasing evidence suggests that neuroinflammation and immune dysregulation play important roles in the pathophysiology of schizophrenia. Elevated levels of pro-inflammatory cytokines, including interleukin-1 beta (IL-1β), have been associated with disease severity and symptom progression.
Risperidone, an atypical antipsychotic, is commonly used as a first-line treatment for schizophrenia and is effective in reducing positive symptoms. However, many patients continue to experience residual symptoms, particularly negative and cognitive symptoms. Therefore, adjunctive therapies targeting alternative pathways, such as inflammation, are being explored to improve treatment outcomes.
Ashwagandha (Withania somnifera) is a traditional medicinal plant with known anti-inflammatory, antioxidant, and neuroprotective properties. Preclinical and clinical studies suggest that Ashwagandha may modulate immune responses, reduce pro-inflammatory cytokines, and improve cognitive and behavioral functions. These properties make it a potential candidate as an adjunctive therapy in schizophrenia.
This study is designed to evaluate the effectiveness of Ashwagandha extract as an adjuvant to risperidone therapy in patients with schizophrenia. Participants diagnosed with schizophrenia are allocated to receive either standard treatment with risperidone alone or risperidone in combination with Ashwagandha extract. The primary outcomes of the study include changes in serum IL-1β levels and clinical symptom severity measured using the Positive and Negative Syndrome Scale (PANSS).
Data are collected at baseline and after the intervention period. Statistical analysis is conducted to compare changes in IL-1β levels and Positive and Negative Syndrome Scale (PANSS) scores between groups. The study aims to determine whether the addition of Ashwagandha extract provides additional benefits in reducing inflammation and improving clinical outcomes compared to standard therapy alone.
The results of this study are expected to contribute to the understanding of the role of immunomodulatory interventions in schizophrenia and to support the development of complementary therapeutic strategies for improving patient outcomes.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
South Sulawesi
-
Makassar、South Sulawesi、インドネシア、90245
- South Sulawesi Mental Hospital (RSKD Dadi)
-
-
参加基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Male patients diagnosed with schizophrenia based on ICD-10/PPDGJ III criteria
- Aged 20-45 years
- Duration of illness ≤ 5 years
- Patients who have passed the acute phase (Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) < 15)
- Receiving risperidone 4 mg/day
- Willing to participate and provide written informed consent
Exclusion Criteria:
- Presence of organic comorbid diseases
- History of substance abuse (NAPZA) within the last 1 year, except caffeine and nicotine
- Use of anti-inflammatory drugs, antibiotics, or antioxidant agents
- Intellectual disability (mental retardation)
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター：Risperidone in combination with a placebo
Participants receive standard antipsychotic therapy with risperidone 4mg/day in combination with a placebo as a control condition for 8 weeks
|
Risperidone is administered as standard antipsychotic therapy according to clinical practice guidelines for the treatment of schizophrenia.
Placebo administered alongside risperidone, matched in appearance to the Ashwagandha preparation, used as a control condition.
|
|
実験的：Risperidone in combination with Ashwagandha extract
Participants receive antipsychotic therapy with risperidone 4mg/day in combination with Ashwagandha (Withania somnifera) extract 1000mg/day as an adjuvant therapy for 8 weeks
|
Risperidone is administered as standard antipsychotic therapy according to clinical practice guidelines for the treatment of schizophrenia.
Standardized extract of Ashwagandha (Withania somnifera) 1000mg/day administered as an adjunctive therapy in combination with risperidone during the study period
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in serum Interleukin-1beta levels
時間枠：Baseline to week 8
|
The primary outcome is the change in serum Interleukin-1beta levels measured to evaluate the anti-inflammatory effect of the intervention
|
Baseline to week 8
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Positive and Negative Syndrome Scale (PANSS) total score
時間枠：Baseline to week 8
|
Change in total Positive and Negative Syndrome Scale (PANSS) score from baseline to Week 8.
The PANSS total score ranges from 30 to 210, with higher scores indicating more severe schizophrenia symptoms.
A reduction in score indicates clinical improvement.
|
Baseline to week 8
|
|
Change in Positive and Negative Syndrome Scale subscale scores (positive, negative, general psychopathology)
時間枠：Baseline to week 8
|
Assessment of changes in Positive and Negative Syndrome Scale (PANSS) subscale scores from baseline to Week 8.
The PANSS includes positive symptom, negative symptom, and general psychopathology subscales.
Higher scores indicate more severe psychopathology, and reductions in scores indicate improvement.
|
Baseline to week 8
|
|
Correlation between change in serum Interleukin-1beta levels and change in Positive and Negative Syndrome Scale (PANSS) total score
時間枠：Baseline to week 8
|
Correlation between changes in serum Interleukin-1 beta levels and changes in Positive and Negative Syndrome Scale (PANSS) total scores from baseline to Week 8 using correlation analysis (e.g., Pearson or Spearman correlation coefficient).
The PANSS total score ranges from 30 to 210, with higher scores indicating more severe schizophrenia symptoms.
|
Baseline to week 8
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Masnaeni Awaliah, MD、Hasanuddin University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- UH25040276
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。